AstraZeneca to invest $2B in Summit Therapeutics, gaining stake in PD-1/VEGF cancer drug push
The equity investment and combination-testing deal centers on Summit's ivonescimab bispecific, which would be tested alongside AstraZeneca's antibody-drug conju
STAT · +14 outlets
Novo Nordisk to pay Hengrui up to $2.6B for once-weekly oral obesity pill
The licensing deal hands Novo a potential challenger to Lilly's market-leading Zepbound as it seeks to calm investor concerns.
Biopharmadive · +13 outlets
FDA approves AbbVie's once-daily Parkinson's drug tavapadon (Juvmo), from $8.7B Cerevel buyout
The first-in-class approval validates AbbVie's multibillion-dollar Cerevel acquisition and adds a new oral option for Parkinson's disease.
Voice of Healthcare · +12 outlets
uniQure shares crash as Huntington's gene therapy data show waning benefit at four years
Analysts had hoped for stronger durability in the four-year readout supporting a potential approval of AMT-130, sending the stock to its worst day in months.
Biopharmadive · +10 outlets
PhRMA names former GOP House majority leader Eric Cantor as new CEO
Cantor takes the helm of the industry lobbying group at a challenging time for pharma policy and pricing.
STAT · +10 outlets
Beam Therapeutics sues YolTech and Serapha Bio, alleging theft of base editing trade secrets
Beam claims a former scientist stole confidential information to co-found a Chinese rival rare disease treatment licensed to Serapha, which denies the charges.
Biopharmadive · +4 outlets
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion
The deal expands Merck's oncology pipeline and is part of a wave of global pharma partnerships with Chinese biotechs.
Yahoo Finance · +14 outlets
Merck, Daiichi pull lung cancer ADC filing after FDA pushback on accelerated approval
The FDA indicated existing data would not support speedy clearance of I-DXd, erasing an edge the partners had over fast-moving competitors.
Biopharmadive · +1 outlets
FDA approves HLB's rivoceranib for bile duct cancer, first Korean firm to directly win anticancer approval
The approval marks a milestone for Korean pharma, with a liver cancer resubmission expected to follow.
finance.biggo.com · +5 outlets
Kodiak Sciences stock doubles as eye disease drug matches Eylea in phase 3
The findings suggest Kodiak may pose multiple threats to Regeneron's Eylea and added more than $3 billion to its market value.
Biopharmadive · +5 outlets
Ultragenyx wins FDA approval for first gene therapy for Sanfilippo syndrome type A
The milestone approval helps Ultragenyx regroup after a tough Angelman program defeat.
The Medicine Maker · +14 outlets
Lawmakers urge Trump to rethink rule that could restrict imported medicines from Canada and overseas
The pending rule could prevent Americans from obtaining medicines from licensed international pharmacies.
STAT · +1 outlets
Adicet Bio's off-the-shelf CAR-T shows promise against lupus in early trial
The gamma delta cell therapy surpassed benchmarks set by personalized CAR-T treatments tested in lupus, pointing to a new era of autoimmune treatment.
Biopharmadive · +6 outlets
Merck discontinues antibiotic Recarbrio in the U.S. despite superbug resistance concerns
The move removes an important antibiotic from the U.S. market amid ongoing worries about antimicrobial resistance.
STAT
Heidi Overton won't get an FDA commissioner vote before the midterms
Health department nominees await Senate votes as the elections reshape the health policy landscape.
STAT · +14 outlets
Iovance raises 2026 revenue outlook sharply, sending stock to over two-year highs
The cancer therapy maker's raised forecast lifted shares about 20%.
TradingView · +5 outlets
Researchers slow neurodegeneration in mice by barring T cells from the brain
The Washington University in St. Louis study suggests limiting certain immune cells could curb neurodegeneration.
STAT
ai3Bio launches with $48M Series A to pursue a different path to an immune reset
Rather than depleting B cells, the company's therapies target a specific group of T helper cells for autoimmune disease.
Biopharmadive